Primary Cells Market: By Type (Hematopoietic, Dermatocytes, Hepatocytes, Gastrointestinal, Lung, Renal, Heart, Musculoskeletal), Origin (Human Primary Cells, Animal Primary Cells), End User (Life Science Research Companies, Research Institutes, Others), and Geography

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Primary Cells Market was valued at USD 1,716.8 million in 2022 and is poised to grow at a CAGR of 10.8% over 2023-2029. Primary cells in biology refers to cells directly taken from living organisms, as opposed to cell lines that have been cultured for extended period and are often used in various biological and medical research applications. The increased demand for potential cancer medicines and treatments by research institutes and companies over cell lines owing to its close resemblance to cells in living organisms, and more accurate representation of cell behavior, function, and responses to stimuli compared to immortalized cell lines. According to Worldwide Cancer Research Fund International, in 2020, an estimated 18.1 million cancer cases around the world with 9.3 million cases in men and 8.8 million in women. Furthermore, an increased need to assess the biological relevance of the toxicity of chemicals, medicines, and compounds, that assist in the detection of potential risks is anticipated to propel the market in upcoming years. Additionally, the advancements and developments in automation, single-cell analysis, and imaging technologies have created opportunities for more comprehensive and detailed studies using primary cells among researchers and drug development companies. Currently, Organ-on-a-Chip technology is becoming popular in the market and involves the recreation of organ-level functions using primary cells on microfluidic devices, enabling more accurate physiological modeling. For instance, in June 2022, CN Bio Innovations launched an organ-on-a-chip device that allows scientists to test potential drugs on living human organ models in conventional cell culture labs without the need for animal models. But the limited availability of certain cell types, and fresh samples owing to cell source limitations along with a limited lifespan in culture may hinder the market growth. However, the rise in pharmaceutical & biotechnology industries, increase in investments by government initiatives, and private firms, and improvement in infrastructure are anticipated to burgeon the market growth during the forecast years.

Primary Cells Market Key Developments
  • In March 2022, Lonza launched human stem cell offerings to provide human cord blood CD34+ hematopoietic stem cells (CB-CD34+ HSCs) in large batch sizes, expanding market need.
  • In May 2020, BioIVT launched high-purity Kupffer cells to its portfolio of human primary hepatic cells to support liver disease drug discovery and development.
  • In June 2018, Lonza launched hepatic stellate cells, Kupffer cells and liver-derived endothelial cells to its extensive hepatocyte’s portfolio with addition of hepatic non-parenchymal cells.

Primary Cells Market Summary

Study Period


Base Year




Largest Market

Asia Pacific

Fastest Growing Market

Asia Pacific
Primary Cell Market Dynamics

The market is expected to rise due to increased requirement for preclinical and investigative biological research including research on intracellular and extracellular communication, the biology of development, and the mechanisms underlying diabetes, Parkinson's disease, and cancer drives the human primary cells market. Furthermore, the limitation of physiological relevance in studies by the continuous passage of cell lines makes human primary cells a more preferred option for researchers and scientists to generate meaningful data that is more predictive of in vivo outcomes. Additionally, the ongoing recent developments, launch, and approval of several products by key companies has led to a surge in market demand. For instance, in April 2023, the Gamida Cell product "Omisirge" (formerly known as Omidubicel and NiCord) received FDA approval. This is the first FDA market approval of an "expanded" cord blood product, which implies the cord blood has been cultivated in a lab to increase the number of cells in a certain way and so make up for the lack of blood-forming stem cells in a cord blood unit.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018-2022), and forecast (2023-2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Primary Cells Market Segmentation

By Type
  • Hematopoietic
  • Dermatocytes
  • Hepatocytes
  • Gastrointestinal
  • Lung
  • Renal
  • Heart
  • Musculoskeletal
By Origin
  • Human Primary Cells
  • Animal Primary Cells
By End User
  • Life Science Research Companies
  • Research Institutes
  • Others

Frequently Asked Questions

The primary cells market valued at USD 1,716.8 million in 2022 and is expected to grow at 10.8% CAGR over the forecast period 2023 – 2029.

The advancements and developments in automation, single-cell analysis, and imaging technologies have created opportunities for more comprehensive and detailed studies using primary cells among researchers and drug development companies.

AllCells, ZenBio Inc. (Research Triangle Park NC), PromoCell, Thermo Fisher Scientific Inc., Cell Biologics Inc., STEMCELL Technologies Inc., Merck KGaA, American Type Culture Collection (ATCC), AG, ATCC, FUJIFILM Irvine Scientific, Inc., Mattek, Axol Bioscience Ltd., Corning Incorporated, and Danaher are a few companies operating in primary cells market.

North America dominates the market with 11.2% CAGR in 2022, and is anticipated to grow with 12.0% CAGR over the forecast period 2023-2029.

  • AllCells
  • ZenBio Inc. (Research Triangle Park NC)
  • PromoCell
  • Thermo Fisher Scientific Inc.
  • Cell Biologics Inc.
  • STEMCELL Technologies Inc.
  • Merck KGaA
  • American Type Culture Collection (ATCC)
  • AG
  • ATCC
  • FUJIFILM Irvine Scientific, Inc.
  • Mattek
  • Axol Bioscience Ltd.
  • Corning Incorporated
  • Danaher